Company news

Shattuck Labs, Inc. news in 2026

Shattuck Labs, Inc.'s news releases, calls and decks from 2026, newest first.

View company

Shattuck Labs Reports Third Quarter 2026 Financial Results and Recent Business Highlights

November 5, 2026

Shattuck Labs Announces Two Poster Presentations at UEG Week 2026

October 13, 2026

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

October 1, 2026

Shattuck Labs Announces Participation in Upcoming September Investor Conferences

September 2, 2026

Shattuck Labs Reports Second Quarter 2026 Financial Results and Recent Business Highlights

August 11, 2026

Shattuck Labs, Inc. Announces Pricing of $75 Million Public Offering

June 10, 2026

Shattuck Labs, Inc. Announces Proposed Public Offering

June 9, 2026

Shattuck Labs Announces Exercise of Outstanding Common Stock Warrants and Provides Financial Update

June 9, 2026

Shattuck Labs Announces Phase 1 Results for SL-325

June 8, 2026

Shattuck Labs to Host Investor Call and Webcast on Phase 1 Clinical Data of SL-325, a Potentially First-in-Class DR3 Blocking Antibody, and Pipeline Update on June 8

June 5, 2026

Shattuck Labs Reports First Quarter 2026 Financial Results and Recent Business Highlights

May 7, 2026

Shattuck Labs Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Highlights

March 4, 2026

Shattuck Labs Announces Participation in Upcoming March Investor Conferences

February 25, 2026

Shattuck Labs Announces Participation in Upcoming Piper Sandler Virtual Novel Targets in Immunology Symposium

February 6, 2026

Decks in 2026